BRIEF-Allakos Announces Phase 1 Trial Results Of Subcutaneous Ak006 In Healthy Volunteers

Reuters10-11

Allakos Inc :

* ALLAKOS ANNOUNCES PHASE 1 TRIAL RESULTS OF SUBCUTANEOUS AK006 IN HEALTHY VOLUNTEERS

* ALLAKOS- AK006 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE

* ALLAKOS INC: TOP-LINE PHASE 1 RESULTS OF INTRAVENOUS AK006 IN PATIENTS WITH CSU ARE EXPECTED IN EARLY Q1 OF 2025

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474715217?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-11 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474715217","market":"us","top_or_hot":-1,"title":"BRIEF-Allakos Announces Phase 1 Trial Results Of Subcutaneous Ak006 In Healthy Volunteers","media":"Reuters","content":"<html><body><p>Allakos Inc   :</p><p>   * ALLAKOS ANNOUNCES PHASE 1 TRIAL RESULTS OF SUBCUTANEOUS AK006 IN HEALTHY VOLUNTEERS</p><p>   * ALLAKOS- AK006 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE</p><p>   * ALLAKOS INC: TOP-LINE PHASE 1 RESULTS OF INTRAVENOUS AK006 IN PATIENTS WITH CSU ARE EXPECTED IN EARLY Q1 OF 2025</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Allakos Announces Phase 1 Trial Results Of Subcutaneous Ak006 In Healthy Volunteers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Allakos Announces Phase 1 Trial Results Of Subcutaneous Ak006 In Healthy Volunteers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 04:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Allakos Inc   :   * ALLAKOS ANNOUNCES PHASE 1 TRIAL RESULTS OF SUBCUTANEOUS AK006 IN HEALTHY VOLUNTEERS   * ALLAKOS- AK006 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE   * ALLAKOS INC: TOP-LINE PHASE ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2474715217","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474715217","pubTimestamp":1728591110,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Allakos Inc   :   * ALLAKOS ANNOUNCES PHASE 1 TRIAL RESULTS OF SUBCUTANEOUS AK006 IN HEALTHY VOLUNTEERS   * ALLAKOS- AK006 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE   * ALLAKOS INC: TOP-LINE PHASE 1 RESULTS OF INTRAVENOUS AK006 IN PATIENTS WITH CSU ARE EXPECTED IN EARLY Q1 OF 2025Source text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALLK":"Allakos Inc."},"translate_title":"简报-Allakos公布健康志愿者皮下注射Ak006的1期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLK":0.9},"content_text":"Allakos Inc   :   * ALLAKOS ANNOUNCES PHASE 1 TRIAL RESULTS OF SUBCUTANEOUS AK006 IN HEALTHY VOLUNTEERS   * ALLAKOS- AK006 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE   * ALLAKOS INC: TOP-LINE PHASE 1 RESULTS OF INTRAVENOUS AK006 IN PATIENTS WITH CSU ARE EXPECTED IN EARLY Q1 OF 2025Source text for Eikon:    Further company coverage:","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474715217"}